EGFR 억제제로서의 치환된 아미노피리딘 화합물

본 발명은 EGFR의 특정 돌연변이된 형태에 대한 억제 활성을 나타내는 신규의 아미노피리딘 화합물 및 약학적으로 허용가능한 조성물을 제공한다. Provided are aminopyridine compounds and pharmaceutically acceptable compositions thereof which exhibit inhibition activity against certain mutated forms of EGFR....

Full description

Saved in:
Bibliographic Details
Main Authors BRYAN MARIAN C, PARK SOL, LEE BYOUNGMOON, KIM HEEJUN, CHOI SU BIN, KUDUK SCOTT, LEE HYUNJOO, YOON YOUNG AE, HYUN KWAN HOON, KIM MISONG, ROBERTSON JAMES CAMPBELL, LEE GYU JIN, KIM TAE KYUN, SIM JAE YOUNG
Format Patent
LanguageKorean
Published 23.04.2024
Subjects
CHEMISTRY
HETEROCYCLIC COMPOUNDS
HUMAN NECESSITIES
HYGIENE
MEDICAL OR VETERINARY SCIENCE
METALLURGY
ORGANIC CHEMISTRY
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS
Online AccessGet full text

Cover

More Information
Summary:본 발명은 EGFR의 특정 돌연변이된 형태에 대한 억제 활성을 나타내는 신규의 아미노피리딘 화합물 및 약학적으로 허용가능한 조성물을 제공한다. Provided are aminopyridine compounds and pharmaceutically acceptable compositions thereof which exhibit inhibition activity against certain mutated forms of EGFR.
Bibliography:Application Number: KR20247009721